Pacific Edge’s (ASX:PEB) Medicare LCD for Cxbladder has landed, and the commercial maths have been rewritten

A 75% price uplift on the next-gen test reshapes Cxbladder’s unit economics as revenue halved

On the face of it, the FY26 result from Pacific Edge (ASX:PEB) looks brutal. Operating revenue almost halved to NZ$11.5m from NZ$21.8m, the net loss after tax widened to NZ$35.8m, and cash on hand fell to NZ$7.8m at 31 March.

But the number that actually matters sits in the post balance date commentary. On 14 May, Medicare contractor Novitas published a draft Local Coverage Determination (LCD) naming Cxbladder Triage and Triage Plus as covered tests for intermediate risk microhematuria patients. An LCD is a decision made by a Medicare Administrative Contractor (MAC) on whether a particular service or item is reasonable and necessary for Medicare coverage within a specific geographic region. The landing of the LCD ends a 13-month coverage gap and brings Triage Plus into the reimbursed product set at US$1,328 per test, a 75% premium to the legacy US$760 price.

Pacific Edge has also been advised it can submit claims on a claim-by-claim basis immediately, ahead of the LCD becoming final by the end of calendar 2026. Combined with the NZ$25.4m placement that closed on 12 May and a retail offer of up to NZ$6m closing 28 May, the company has bought runway to convert policy into revenue.

Why the US$1,328 price tag does more than the headline suggests

Pacific Edge’s legacy tests, Triage and Monitor, are reimbursed by Medicare at US$760 each. Triage Plus, the next generation hematuria test, has been priced by Medicare at US$1,328, and it is now in the draft LCD alongside Triage.

Management’s plan is to progressively shift US customers from the legacy tests onto Triage Plus. At roughly the same testing volume, that re-pricing alone lifts revenue per test by 75% before any volume recovery from Medicare re-coverage shows up.

We think this is the single most important number in the result. The unit economics of running a US sales team only work above a threshold revenue per test, and US$1,328 is the price that arguably puts the business on a credible path to profitability rather than just survival.

FY26 volumes show the real cost of a year without Medicare

Total laboratory throughput fell 16.3% to 24,190 tests, with commercial tests down 23.8% to 18,783. US total tests dropped 21.4% as the company simultaneously lost Medicare coverage and tried to transition customers from Detect to Triage.

The US sales force was cut hard. Average sales headcount fell to 8 full-time equivalents in Q4 26 from a peak of 33 in Q3 23, while tests per ordering clinician rose to 5.4 from 4.8 the prior quarter. That is operating leverage in waiting if volumes return.

Second-half cash burn dropped to NZ$2.4m per month from NZ$3.3m in the first half, and FY27 is targeted at NZ$2.5m per month. The skeptical read is that these cuts went deep because they had to, and rebuilding the salesforce will eat back some of those savings.

The capital raise buys runway, but the LCD timeline still rules

The NZ$25.4m placement priced at NZ$0.17 plus up to NZ$6m from the retail offer gives Pacific Edge roughly NZ$31m of fresh capital. At an FY27 target burn of NZ$2.5m a month, that is around 12 months of runway before any revenue uplift from claim-by-claim Medicare billing flows through.

Novitas has until 15 May 2027 to either finalise or withdraw the draft LCD, and the company’s own estimate is final effective coverage by end of calendar 2026. The auditor has flagged material uncertainty around the LCD outcome and the need for further funding, which investors should note rather than dismiss.

Our concern is timing. Claim-by-claim reimbursement can start now, but Medicare cash receipts typically lag testing by months, and the appeals backlog from the coverage gap is unaccrued revenue that may or may not be collected.

The Investors Takeaway for Pacific Edge

The draft LCD reshapes the Pacific Edge story from survival mode into a commercial execution story. Triage Plus at US$1,328 is the lever, and APAC is already showing what a leaner, repriced business looks like with FY26 APAC cash burn down roughly 40% on the prior year.

We will be watching two things. First, the pace at which US customers adopt Triage Plus once claim-by-claim billing flows are established. Second, whether the LCD timeline holds. Slippage past calendar 2026 would push the company back toward another raise.

Investors looking for more coverage of ASX-listed diagnostics names can find our broader work at stocksdownunder.